Intestinal Microbiota and Visceral Pain in Chronic Intestinal Pseudo-Obstruction Syndrome (CIPO)
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Sep 20, 2024
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Intestinal Microbiota and Visceral Pain in Chronic Intestinal Pseudo-Obstruction Syndrome (CIPO)," aims to explore how the bacteria in the intestines might affect pain in patients with a condition called CIPO. CIPO is a rare disorder that affects how well the intestines move food and can cause severe abdominal pain, especially during flare-ups triggered by infections, stress, or malnutrition. The researchers believe that changes in the intestinal bacteria, known as dysbiosis, may lead to increased sensitivity to pain in these patients. They want to see if there is a specific pattern of bacteria in CIPO patients that contributes to this pain.
To participate in the trial, candidates must be between the ages of 1 and 21 and have been diagnosed with CIPO for at least a year. This means they need to have had problems like recurrent intestinal swelling, difficulty getting enough nutrition, changes in how their intestines work, or specific genetic markers. Participants will be asked to give their consent, along with their parents or guardians, to take part in this important research. The study is not yet recruiting participants, but it aims to provide valuable insights into managing pain in young people with CIPO.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient aged 1 to 21 years
- • Patient diagnosed with CIPO for at least 12 months (= patients meeting at least 2 of the following 4 criteria: 1. Recurrent episodes of intestinal dilatation, 2. Inability to maintain nutrition, 3. Intestinal neuromuscular alteration and 4. Genetic variants.)
- • Patient with an ileal or colonic digestive diversion
- • Signature of informed consent by both holders of parental authority and agreement in principle given orally by the subject;
- • Patients affiliated to a social security scheme
- Exclusion Criteria:
- • -
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Patients applied
Trial Officials
Alexis MOSCA, MD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported